Canada's Valeant Pharma posts quarterly net loss

Thu Oct 31, 2013 6:15am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Oct 31 (Reuters) - Valeant Pharmaceuticals International Inc , Canada's biggest publicly traded drugmaker, posted a quarterly net loss that it attributed in part to restructuring and impairment charges.

Valeant posted a net loss of $973 million, or $2.92 per share, for the third quarter, compared with a profit of $7.6 million, or 2 cents, a year earlier.

Cash earnings, or profit adjusted for one-time items, was $486 million, or $1.43 per share.